The answer to misinformation is not simply to say no.
When a famous actor claimed on a podcast that ivermectin had cured his friends of advanced cancer, he set in motion something medicine has long feared: the power of a single compelling voice to reshape the choices of the vulnerable. Prescriptions for the antiparasitic drug more than doubled in the United States, not because science had advanced, but because celebrity had spoken. The distance between laboratory promise and clinical proof is vast, and it is precisely in that gap — where hope outpaces evidence — that patients with cancer can lose the time they cannot afford to lose.
- A single podcast appearance by Mel Gibson in January triggered a measurable national surge in ivermectin prescriptions for cancer, documented by UCLA researchers in a peer-reviewed study.
- The danger is not the drug itself but the displacement — patients delaying or abandoning chemotherapy, radiation, or immunotherapy that has been proven to extend life.
- In oncology, timing is everything: treatment windows close, disease progresses, and the sequence of interventions matters in ways that cannot be recovered once lost.
- Medical experts are calling for physicians to engage rather than dismiss — to explain the gap between lab results and clinical proof, and to guide patients back toward evidence-based care.
- The surge was especially pronounced among men and patients in the South, raising concerns about which communities are most exposed to health misinformation and least protected from its consequences.
In January, actor Mel Gibson told a podcast audience that three of his friends had recovered from advanced cancer after taking ivermectin. Within months, prescriptions for the antiparasitic drug to treat cancer had more than doubled across the United States. A study published in JAMA Network Open by UCLA researchers documented the surge and posed an urgent question: how many patients were now pursuing a treatment with no proven safety or efficacy in humans?
The science is not without nuance. Ivermectin does show anticancer activity in laboratory and animal studies — as does fenbendazole, another antiparasitic Gibson mentioned. But the distance between a petri dish and a human body is enormous. No clinical trial has ever demonstrated that either drug is safe or effective for treating cancer in people. Of all molecules that enter clinical trials, only 5 to 10 percent ever reach the market. What works in cells rarely works in bodies.
The real harm, oncologists warn, is not the drug itself but what it replaces. Patients who turn to unproven treatments often delay or abandon chemotherapy, radiation, immunotherapy, or surgery — interventions with demonstrated survival benefits. In cancer care, timing is not incidental; it is often decisive. The window of opportunity closes. The senior author of the UCLA study noted that the spike was especially visible among men and patients in the South, sharpening fears that vulnerable populations were trading proven treatment for unverified hope.
Clinical oncologist Clarissa Baldotto describes the full cascade of risk: delayed treatment, compromised survival, dangerous drug interactions, false reassurance, and the irreversible loss of a therapeutic window. Her counsel to colleagues is not to dismiss patients who arrive with questions shaped by social media, but to engage them — to explain the difference between scientific hypothesis and clinical evidence, and to offer guidance grounded in reliable data.
Patients deserve skepticism toward miraculous promises, isolated testimonies, and advice from those without medical training. Trustworthy guidance comes from medical societies, academic institutions, regulatory agencies, and above all from the physicians who know their case. The stakes are not abstract. They are measured in months of life, in chances that, once missed, do not return.
In January of last year, actor Mel Gibson made a claim on a podcast that would ripple through American medicine: three of his friends, he said, had recovered from advanced cancer after taking ivermectin. Within months, prescriptions for the drug to treat cancer more than doubled across the United States. A study published in JAMA Network Open, conducted by researchers at UCLA, documented the surge and raised an urgent question: how many patients were now pursuing a treatment with no proven safety or efficacy in humans?
The science behind the concern is straightforward. Ivermectin, an antiparasitic drug approved in the United States for treating certain parasitic infections, does show anticancer activity in laboratory settings and in animal models. So does fenbendazol, another antiparasitic compound Gibson mentioned in his interview. But there is a vast distance between what happens in a petri dish or a mouse and what actually works in a person. No human clinical trial has ever demonstrated that either drug is safe or effective for treating cancer. That gap—between laboratory promise and clinical proof—is where the danger lives.
Clarissa Baldotto, a clinical oncologist and president of the Brazilian Society of Clinical Oncology, explains the problem with clarity. Most substances that look promising in the lab never make it to human testing. Of the molecules that do enter clinical trials, only between 5 and 10 percent ever reach the market. The journey from hypothesis to medicine is long, expensive, and most candidates fail. What works in cells does not work in bodies. What works in mice does not work in people. This is not opinion; it is the accumulated lesson of decades of drug development.
But the real harm lies not in taking ivermectin itself—the immediate side effects are often manageable—but in what patients do instead of proven treatment. When someone with advanced cancer chooses an unproven drug, they are not simply adding a therapy; they are often delaying or abandoning chemotherapy, radiation, immunotherapy, or surgery that has been shown to extend life. In oncology, timing matters profoundly. The sequence of treatments matters. The window of opportunity closes. John Mafi, the senior author of the UCLA study, framed the concern plainly: when prescriptions for an unproven cancer treatment more than double after a single podcast, especially among men and people in the South, it raises the fear that patients are skipping or postponing treatments known to work in favor of something whose efficacy has never been proven.
Baldotto describes the cascade of risks: delayed treatment, compromised survival, reduced quality of life, dangerous drug interactions, incorrect dosing, a false sense of security, and the loss of a genuine therapeutic window. Cancer is not a simple disease. It requires precision, timing, and evidence-based care tailored to the individual patient. Easy answers do not exist.
Yet patients arrive at oncology appointments having watched videos, read personal testimonies, and encountered promises of miraculous cures on social media. Baldotto's response to this reality is not dismissal but engagement. The role of the physician, she argues, is to welcome the patient's questions, to explain the difference between scientific hypothesis and clinical evidence, to assess risk, and to offer guidance grounded in reliable data. The answer to misinformation is not simply to say no. It is to explain why a treatment cannot yet be considered medicine, and what dangers it carries.
Patients should be skeptical of promises of quick cures, miraculous treatments, isolated testimonies without scientific backing, conspiracy theories about medicine, and advice from people without medical training. Trustworthy information comes from medical societies, academic institutions, regulatory agencies, peer-reviewed scientific publications, and most importantly, from conversations with the medical team treating them. The stakes are not abstract. They are measured in months of life, in the chance to see another season, in whether a person gets to choose how their story ends.
Citas Notables
When prescriptions for an unproven cancer treatment more than double after a single podcast, it raises concern that patients may be skipping treatments known to work in favor of something whose efficacy has never been proven.— John Mafi, UCLA study author
In oncology, time and sequence of treatment matter greatly. There are risks of side effects, drug interactions, incorrect dosing, false sense of security, and loss of therapeutic opportunity.— Clarissa Baldotto, clinical oncologist and president of the Brazilian Society of Clinical Oncology
La Conversación del Hearth Otra perspectiva de la historia
Why did Gibson's claim have such immediate effect? Couldn't people tell the difference between a story and evidence?
Because the story was personal and the evidence was abstract. Three friends recovered. That's concrete. A clinical trial is years away and involves statistics. People believe what they can picture.
But surely doctors pushed back immediately?
Some did. But by then the prescriptions had already doubled. The damage was done before the correction could catch up. Misinformation travels faster than refutation.
What's the actual risk if someone takes ivermectin while also doing chemotherapy?
That's the question that keeps oncologists awake. Drug interactions, wrong dosing, false confidence that they're doing enough. But worse: the patient who stops chemo because they believe the ivermectin is working. That's where survival rates collapse.
How does a doctor even have this conversation without sounding dismissive?
By listening first. By saying, "I understand why this appeals to you. Let me explain what we actually know." By treating the patient as someone with legitimate fear, not someone who's stupid.
Is there any chance ivermectin actually works and the trials just haven't happened yet?
Technically possible. But unlikely. And irrelevant to the patient right now. What matters is what we can prove today, not what might be true someday.
So what happens to these patients who started taking it?
Some will be fine. Some will delay treatment they needed. Some will die from cancer that could have been treated. We won't know the full cost for years.